s u m m a r y p o i n t s • The pharmacokinetics of the traditional oral opioids do not match the time course of breakthrough cancer pain, a common and distinct component of cancer pain which has a negative impact on quality of life for the patient.
Introduction
The definition and appropriate management of cancer-related breakthrough pain has been the subject of much discussion within the palliative medicine fraternity in recent years. This distinct component of cancer pain negatively impacts on the quality of life for the patient and studies have found that up to 95% of patients with background pain experience breakthrough pain. 1
Definition, characteristics and current management
A recent task group from the Association of Palliative Medicine of Great Britain and Ireland defined breakthrough cancer pain (BTCP) as "a transient exacerbation of pain that occurs either spontaneously or in relation to a specific predictable or unpredictable trigger, experienced by patients who have relatively stable and adequately controlled background pain". Incident pain (precipitated by movement or activity and further divided into volitional, non-volitional and procedural) and spontaneous pain, falls within this definition. 2 The results from the first phase of an ongoing international, multicentre observational study that surveyed 200 patients with BTCP from the UK, Sweden and Denmark, found that patients experienced 3 episodes per day with a median duration per episode of 60 minutes. Patients described these as moderate to severe in 96% of episodes. Activities of daily living including ability to sleep, walk and get on with other people were affected in 90% of patients. Oral drugs were used as rescue medication in 95% of patients with a median time of 20 minutes to first noticing a reduction in pain and a median time to peak effect of 30 minutes. 3 Current management uses supplemental analgesia (rescue medication) at a dose proportional to the total round the clock opioid dose. However, the pharmacokinetics of the oral opioids used to relieve BTCP e.g. morphine sulphate immediate release/ oxycodone immediate release, do not match the time course of BTCP. These agents take 20 -30 minutes to onset of action with a duration of approximately 4 hours. Multiple use of such analgesic agents results in ineffective treatment of BTCP episodes together with the additional problem of increased adverse effects, particularly sedation and confusion.
New approaches that better reflect the nature of BTCP are required. Potent agents with fast onset and short duration are preferable; fentanyl and alfentanil are two such agents. 
Agents
Fentanyl is a synthetic opioid phenylpiperidone derivative with agonist activity at the mu-opioid receptor. It is sequestrated into body fat and acts predominantly supraspinally in the thalamus with a minimal effect on the dorsal horn. It is highly lipophilic and crosses the blood brain barrier better than morphine. It has approximately 100 times the potency of morphine and causes less constipation, nausea and vomiting. Metabolism is by CYP3A4 to norfentanyl, an inactive metabolite. In renal impairment, fentanyl is relatively safe, although clearance may be reduced. It has a rapid onset and short duration of action with peak effects within 30 minutes. 100mcg given by intravenous injection produces analgesia for 10 to 20 minutes, while 1000mcg produces analgesia for 60 minutes. 4, 5 The transdermal preparation of fentanyl is used in palliative care patients for background analgesia.
Alfentanil is a synthetic opioid with activity at the mu-opioid receptor. When given intravenously the peak analgesic effect occurs within 90 seconds and lasts for 5-10 minutes. When compared with fentanyl after single intravenous doses, it has a more rapid onset of action (0.75 minutes vs 1.5 minutes), a shorter duration of action (30 minutes vs 60 minutes) 6,7,8 and an analgesic potency approximately one quarter that of fentanyl; it has approximately 20 times the potency of parenteral morphine. 9 Elimination is mainly by metabolism in the liver with an elimination half-life of 90 minutes. It is licensed for intravenous (IV) injection or infusion. 10 It is used as a step 3 analgesic in palliative care patients with renal impairment and is given by subcutaneous (SC) injection or continuous SC infusion both of which are off-licence routes of administration.
New routes of administration
While there have been no new opioids introduced to the UK market since tramadol in 1994, 11 there has been a move in recent years by pharmaceutical companies to use different routes of administration for older established analgesic agents in combination with novel technology. The use of different transmucosal routes e.g. buccal, sublingual or nasal has specific advantages over the oral route; the large surface area which is well vascularised and highly permeable results in efficient drug absorption through the mucosal surface and rapid drug transport to the systemic circulation avoiding the gastrointestinal tract and first pass hepatic metabolism. 12 Because of their high lipophilicity and consequent poor oral bioavailability, fentanyl and alfentanil are ideal for oral transmucosal or nasal transmucosal administration.
Products
Alfentanil has been available as a buccal/nasal spray for several years. This is an unlicensed product manufactured under a specials licence by Torbay Pharmacy Manufacturing Unit (www.torbaypmu.nhs.uk).
It is formulated as a 5mg/5ml solution and comes with both buccal and nasal spray adaptors. Once opened it is stable for 28 days. Each 0.14ml actuation contains 140mcg alfentanil. Doses range from 2 to 12 sprays (280mcg to 1680mcg alfentanil). It is appropriate for BTCP but is of limited use due to the low concentration and resulting impracticality around the number of sprays required. It may have a place for short, planned procedural episodes eg dressing changes.
Several relevant formulations of Fentanyl for BTCP are now available (see Table 1 ):
• Lozenge (Actiq®) introduced in 2002; each oral transmuscosal fentanyl citrate (OTFC) compressed lozenge has an integral oromucosal applicator and is intended for buccal administration. 13 • Buccal tablet (Effentora®) introduced in April 2008); uses a delivery technology which produces an effervescent reaction that enhances the rate and extent of Fentanyl absorbtion through the buccal mucosa. Transient pH changes optimise dissolution and membrane permeation. 14 • Sublingual tablet (Abstral®) introduced in September 2008; a quick dissolving sublingual tablet formulation. Within the tablet, ordered units of fine drug particles are attached to coarser carrier particles. Rapid disintegration of the tablet occurs; the ordered units adhere to the oral mucosa, the carrier particles dissolve and release the active compound which dissolves and is absorbed over the oral mucosa. 15, 16 • Nasal spray (Instanyl®) introduced in October 2009, the first nasal preparation of Fentanyl and buffered with phosphate solution. 17 All these products are licensed for breakthrough pain in patients using opioid therapy for chronic cancer pain taking at least 60mg oral morphine or its equivalent per day or at least 25mcg/hour of fentanyl transdermal for at least a week.
All apart from the lozenge (Actiq®) are intensively monitored medicines identified by the black triangle symbol (▼) in the BNF. Such drugs are monitored intensively by the Commission on Human Medicines (CHM) and the Medicines and Healthcare products Regulatory agency (MHRA). All suspected adverse reactions should be reported to the MHRA via the yellow card reporting scheme (http://yellowcard.mhra.gov.uk). 18
Evidence
The evidence base supporting the efficacy and safety of these new formulations is generally poor with few published studies; the majority are comparisons against placebo. Currently there are minimal comparator studies and none with the standard treatment, morphine immediate release oral solution. This study is the first to compare two products specifically developed for the treatment of breakthrough pain. It does have design limitations. It was open label rather than double-blind due to practical difficulties with two completely different formulations. However the crossover design where patients acted as their own controls aimed to minimise potential confounding external factors. The comparator chosen (OTFC) was not the standard treatment for breakthrough pain (morphine immediate release oral liquid), but at the time of the study it was the only preparation with a specific marketing authorisation. It also, in terms of its pharmacokinetic profile, more closely matched the characteristics of breakthrough pain. The number of participants was relatively low and there was a high drop out rate; 38% of those randomised did not complete the study for a variety of reasons. However the sample size required to adequately power the study (n=85) was just achieved (n=86) and an intention to treat analysis was performed. It should be noted that studies in patients with advanced cancer as in this population are difficult logistically in terms of recruiting numbers because of strict exclusion criteria and in terms of the ability of the patients to complete the study as their disease progresses. Nycomed, the manufacturer of Instanyl®, funded the study and also took responsibility for the study design and conduct. 19 Practical issues
• The lozenge requires a degree of dexterity and patience by the user. It is unsatisfactory in about 25% of patients, who fail to obtain relief or have unacceptable side effects. 4
• The buccal tablet takes up to 25 minutes to dissolve and leaves a distinct taste in the mouth.
• The buccal and sublingual tablets can be difficult to extract from their respective packaging. A specific technique is required. The nasal spray is packed in a child-resistant outer box. These packaging issues may be problematic for weak and frail patients.
• Any of the oral transmucosal preparations should be used with caution in patients with mouth wounds or mucositis as there is an increased risk of systemic opioid absorption from damaged mucosa.
Probably the most interesting difference with respect to dose titration with these new preparations is the lack of proportionality between regular background analgesic dose and breakthrough doses. All of these new products should be titrated from the lowest dose, irrespective of the level of background analgesia. It also is important to note that the lozenge, buccal, sublingual and intranasal preparations are not interchangeable. If transferring from one to another, then the new product must be re-titrated.
Forthcoming products
Nasalfent, marketed by Archimedes Pharma is a fentanyl nasal spray incorporating PecSys™ technology. Pectin, present in a low viscosity aqueous solution of fentanyl citrate, forms a thin gel layer on contact with the calcium ions present in nasal mucosal fluid. Absorption of fentanyl across the nasal mucosal membrane is modulated, allowing rapid but controlled absorption into the systemic circulation together with an increased duration of action. This technology avoids high levels of drug and dripping or swallowing of drug solution which are problems often associated with simple solutions used as nasal sprays. 22 Phase 3 trial data has demonstrated pain relief within 5 minutes of dosing. 23 The manufacturer submitted a marketing authorisation application with the European Medicines Evaluation Agency in April 2009 and submitted a New Drug Application with the US Food and Drug administration in September 2009. The product is targeted for launch from mid-2010. r e v i e w s i n p a i n Fentanyl BEMA (bio-erodible muco-adhesive) discs developed by BioDelivery Sciences International introduces a novel drug delivery system; a buccal soluble film consisting of a small bio-erodible polymer film for application to the inner lining of the cheek. It is designed to adhere to oral mucosa in less than 5 seconds, to optimise delivery across the oral mucosa and to completely dissolve within 15 -30 minutes. 24 The fentanyl buccal soluble film (Onsolis marketed by Meda Pharmaceuticals) was approved by the FDA in July 2009 and is available in the US under a restricted distribution programme. It is available in a range of strengths; 200mcg, 400mcg, 600mcg, 800mcg and 1200mcg.
This product has an absolute bioavailability of 71%. Approximately 51% is absorbed from the buccal mucosa with the remainder swallowed and absorbed from the GI tract. Of the swallowed fentanyl approximately 20% of the dose escapes hepatic and intestinal first pass elimination and becomes systemically available. 25 In a study that compared the relative bioavailability of Onsolis and Actiq® in 12 adult normal volunteers, the rate and extent of fentanyl absorption were considerably greater with Onsolis (62% greater maximum plasma concentration and 40% greater systemic exposure). 26 Efficacy and safety in treating BTCP has been demonstrated in placebo-controlled studies. 27 It is currently under review in the EU with approval expected sometime in 2010. It is likely to be marketed as Breakyl.
Fentanyl multidose dry powder inhalers
At least three preparations are in development using different technologies to deliver fentanyl via the inhaled route; Fentanyl Taifun, a multi-dose dry powder inhaler, 28 Stacatto Fentanyl AZ-003, a breath actuated inhaler 29 and AeroLEF, a breath-actuated jet nebuliser. 30 Early reports demonstrate good efficacy in treating breakthrough pain.
Conclusion
After years of suboptimal symptomatic management of BTCP we now have access to several relevant and more appropriate licensed products, with the promise of others to follow. These utilise the pharmacokinetic properties of fentanyl and allow wider patient choice. As with any new drug delivery system there are cost implications. However in patients for whom BTCP dramatically affects their quality of life, the use of these agents may be of real benefit. More robust comparator studies are required to help guide product choice. 
